BRENTWOOD, Tenn. / Dec 18, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference being held Jan. 13-16, 2025, in San Francisco.
The management team will present at the conference beginning at 2:15 p.m. PT on Tuesday, Jan. 14, 2025. A live audio webcast of the presentation will be available at the investor relations section of the Company’s website, at ir.ardenthealth.com, and a replay will be available for 90 days using the same link.
In conjunction with the conference, the Ardent management team will be available to participate in one-on-one meetings with investors registered to attend the conference. Interested investors should contact their J.P. Morgan representative to schedule meetings.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.
Last Trade: | US$12.69 |
Daily Change: | 0.16 1.28 |
Daily Volume: | 166,981 |
Market Cap: | US$1.820B |
August 05, 2025 May 06, 2025 March 31, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load